Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of tucatinib + trastuzumab in previously treated HER2-altered advanced solid tumors
2020-004873-29Phase 2Active
- Sponsor
- Seagen Inc.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucatinib, trastuzumab and fulvestrant in Nonhematologic neoplasms and cholangiocarcinoma (CCA) (2 arms), sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate. Started Mar 2021; status: active.
02
Drugs
03
Conditions
Nonhematologic neoplasmscholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2020-004873-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004873-29.